Business

Grupo Ferrer Internacional, which markets Alexza Pharmaceuticals' Adasuve inhaled loxapine in the EU, Latin America, and the CIS countries, will acquire 2 million shares of Alexza common stock at $4 per share, the companies have announced. The amendment to the two companies' agreement on Adasuve will make Ferrer the largest shareholder in Alexza and includes … [Read more...] about Ferrer to become Alexza Pharmaceuticals’ largest shareholder

Ferring Pharmaceuticals has announced that it has reacquired desmopressin acetate (DDAVP), which is approved as a nasal spray and a number of other formulations, from Sanofi. Ferring originally developed desmopressin, which is a synthetic form of vasopressin and is used to reduce frequent urination among other conditions. In 2007, the FDA announced that the … [Read more...] about Ferring reacquires rights to desmopressin nasal spray

Retrophin has announced that Turing Pharmaceuticals will pay $3 million up front for three of Retrophin's products, including Syntocinon oxytocin nasal spray and ketamine. According to the company, the agreement includes the resignation of Retrophin founder Martin Shkreli. Shkreli's Twitter profile identifies him as the CEO of Turing Pharmaceuticals. The company … [Read more...] about Retrophin divests Syntocinon nasal spray to Turing Pharmaceuticals

Boehringer Ingelheim has announced that the Striverdi Respimat olodaterol soft mist inhaler is now available in the United States. The FDA approved Striverdi Respimat for the treatment of COPD in July 2014. The company said that a savings program will be available, allowing most patients to get the inhaler free for a period of time. The card will provide the … [Read more...] about Striverdi Respimat launched in the US

Teva Pharmaceutical has completed a strategic review of its core therapeutic areas and will focus its development efforts on central nervous system and respiratory drugs, the company has announced. According to the announcement, 14 drug development programs currently underway at Teva in other therapeutic areas will be divested or discontinued, with the $150-200 … [Read more...] about Teva to focus on respiratory, CNS drug businesses

According to Lightlake Therapeutics, an investor will receive a 0.98% interest in the company's naloxone nasal spray for the treatment of opioid overdose for a $500,000 investment and a 1% interest in intranasal naloxone for the treatment of binge eating disorder for an additional $500,000. In July 2014, the company filed an IND for the opioid reversal indication … [Read more...] about Lightlake gets $1 million investment in two nasal spray products

Discovery Laboratories has received a Phase 2 Small Business Innovation Research Grant (SBIR) from the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) for development of aerosolized KL4 surfactant for the treatment of lung damage caused by radiation. The initial award of $1 million can be supplemented by an … [Read more...] about Discovery Labs gets up to $3 million to develop KL4 aerosol for the treatment of radiation induced lung damage